[A case of distal cholangiocarcinoma with high sensitivity to neoadjuvant chemoradiation therapy].

Yoichi Haji, Masamichi Mizuma, Hiroki Hayashi, Kei Nakagawa, Takaho Okada, Hideo Otsuka, Shigeru Ottomo, Naoaki Sakata, Koji Fukase, Hiroshi Yoshida, Tohru Onogawa, Fuyuhiko Motoi, Takeshi Naito, Toshiki Rikiyama, Y. Katayose, Shinichi Egawa, Michiaki Unno

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

We hypothesized that neoadjuvant chemoradiation therapy for cholangiocarcinoma (NACRAC) using gemcitabine would improve the prognosis of resected cases. Phase II trial of NACRAC is ongoing. We report a very effective case to NACRAC for distal cholangiocarcinoma, which markedly reduced the size and levels of the tumor markers. The patient was a 50- year-old man who presented jaundice. Serum tumor markers were clearly elevated, and abdominal CT scan revealed an enhanced mass in the lower bile duct, a dilatation of the intrahepatic to the middle bile duct and a swollen regional lymph node. After NACRAC, the tumor markers were decreased within a normal range. Also on CT scan, the main tumor was slightly detectable and the swollen node was reduced more than 30% in short diameter. Therefore, the effect of NACRAC was considered PR in RECIST guidelines (ver.1 .1). Pancreaticoduodenectomy was performed 2 weeks after NACRAC. No perioperative complications occurred. Pathological examination showed a good response, Grade 2b on Oboshi-Shimosato's classification. In this case, NACRAC had a good effect in imaging and pathological findings as well as in the tumor markers. Therefore, the neoadjuvant chemoradiation therapy has a potential to improve the prognosis for cholangiocarcinoma.

Original languageEnglish
Pages (from-to)2426-2428
Number of pages3
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume38
Issue number12
Publication statusPublished - 2011 Nov

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of '[A case of distal cholangiocarcinoma with high sensitivity to neoadjuvant chemoradiation therapy].'. Together they form a unique fingerprint.

Cite this